Chemours Co
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
CC$13.48+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Consolidated Statements of Operations (Unaudited)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net sales | $1,368 | $1,362 |
| Cost of goods sold | 1,132 | 1,078 |
| Gross profit | 236 | 284 |
| Selling, general, and administrative expense | 123 | 137 |
| Research and development expense | 27 | 28 |
| Restructuring, asset-related, and other charges | 33 | 4 |
| Total other operating expenses | 183 | 169 |
| Equity in earnings of affiliates | 8 | 13 |
| Interest expense, net | (66) | (63) |
| Other income, net | 5 | 5 |
| Income before income taxes | — | 70 |
| Provision for income taxes | 4 | 16 |
| Net (loss) income | (4) | 54 |
| Net (loss) income attributable to Chemours | $(4) | $54 |
| Per share data | ||
| Basic (loss) earnings per share of common stock | $(0.03) | $0.36 |
| Diluted (loss) earnings per share of common stock | (0.03) | 0.36 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.